Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Lymphoma 5Neoplasms 2Multiple Myeloma 2Recurrence 1Primary Myelofibrosis 1Myelodysplastic Syndromes 1Leukemia 1Hematologic Neoplasms 1Central Nervous System Neoplasms 1

Interventions

Cyclophosphamide 260fludarabine phosphate 163Methotrexate 124Rituximab 112Cytarabine 109Filgrastim 106fludarabine 92Busulfan 86Peripheral Blood Stem Cell Transplantation 83Etoposide 82Vincristine 80Radiotherapy 79Tacrolimus 73Mycophenolic Acid 72Antilymphocyte Serum 68Whole-Body Irradiation 66Melphalan 63Dexamethasone 63Cyclosporine 58Doxorubicin 51Prednisone 44Methylprednisolone 44Alemtuzumab 44Mercaptopurine 41Granulocyte Colony-Stimulating Factor 40pegaspargase 35Daunorubicin 34Clofarabine 33Thiotepa 31Asparaginase 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × ridaforolimus × Lymphoid × Clear all
NCT00086125 2015-08-19

Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 2 Completed
57 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Recurrence, Hematologic Neoplasms, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡